BD Oncomark™ Anti-Human FMC7 FITC/CD23 PE/CD19 PerCP-Cy™5.5
Description
Clone FMC7, is generated from the fusion of P3-NS1-1-AG4-1 mouse myeloma cells with spleen cells from BALB/c mice immunized with human B-lymphoblastoid cell line HRIK. The CD23 antibody, clone EBVCS-5, is derived from hybridization of Sp2/0 mouse myeloma cells with spleen cells from BALB/c mice immunized with in vitro– transformed EBV cell line. The CD19 antibody, clone SJ25C1, is derived from hybridization of Sp2/0 mouse cells with spleen cells from BALB/c mice immunized with NALM1 + NALM16 cells. The FCM7 antibody recognizes a 105-kilodalton (kDa) membrane glycoprotein expressed on a subset of B lymphocytes. The CD23 antibody recognizes a human B-lymphocyte differentiation antigen, with a molecular weight of 45 kDa, that is the low-affinity Fc epsilon receptor. The CD19 (SJ25C1) antibody recognizes a 90-kDa antigen that is present on human B lymphocytes.
Preparation And Storage
Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.
| Description | Clone | Isotype | EntrezGene ID |
|---|---|---|---|
| N/A | N/A | IgM, ,IgG1, κ,IgG1, κ | N/A |
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.